pentapeptide raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-03-23 and is reviewed periodically as new material appears.
Structural features distinguish the molecule from earlier secretagogues. An alpha-aminoisobutyric acid residue near the N-terminus and a D-naphthylalanine substitution increase receptor affinity, while C-terminal amidation improves resistance to exopeptidases. These modifications are associated with reduced stimulation of appetite and of the hypothalamic-pituitary-adrenal axis compared with hexarelin or growth hormone releasing peptide-6. Whether the same profile applies at every dose level studied is a matter of ongoing investigation rather than settled consensus.
Ipamorelin is a synthetic pentapeptide that acts as an agonist at the ghrelin receptor, also called the growth hormone secretagogue receptor type 1a. Its sequence incorporates non-natural residues, which slows enzymatic breakdown relative to short native peptides. In laboratory and early clinical work the compound is described as a selective growth hormone secretagogue because it raises growth hormone with comparatively little effect on other pituitary outputs. The degree to which that selectivity holds across species and dosing regimens remains an open question in the published literature.
Compared with older secretagogues such as hexarelin or GHRP-6, ipamorelin shows weaker stimulation of cortisol, prolactin, and appetite in the animal models used for early characterization. Whether that selectivity is preserved across longer human exposures remains an open question, because published clinical data are limited in size and duration. Reported effects on food intake are generally described as modest. The compound is therefore treated in the literature as a relatively selective research tool rather than a fully characterized therapeutic agent.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class of compounds. Researchers at a pharmaceutical company first described it in the 1990s while screening small peptides for growth hormone releasing activity. Its chain contains five amino acid residues, two of which are non-natural building blocks, including 2-aminoisobutyric acid and a naphthylalanine derivative. The molecule was designed to act at the ghrelin receptor while avoiding several effects observed with earlier secretagogues.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H49N9O5 | Reported for the free peptide |
| Molecular mass | 711.85 Da | Monoisotopic value |
| Residue motif | Aib-His-D-2-Nal-D-Phe-Lys-NH2 | Non-natural residues at positions one and three |
| Primary target | GHSR-1a | Ghrelin receptor, G protein coupled |
| Reported plasma half-life | About two hours | Values vary with assay and subject group |
Lyophilized material is generally stored frozen and protected from light and moisture. Typical recommendations place dry powder at temperatures well below freezing, while reconstituted solutions are kept cold and used within a defined window. Repeated freezing and thawing should be avoided because it can promote aggregation and loss of material. The choice of solvent matters as well; compatibility with the intended diluent should be checked before preparation. These handling practices aim to preserve both the quantity and the integrity of the peptide.
Verification of identity and purity relies on analytical methods used across peptide chemistry. Reverse-phase high-performance liquid chromatography separates components by hydrophobicity and provides a purity estimate. Mass spectrometry confirms molecular mass and helps detect modifications. Together these techniques give complementary information about whether a sample matches its expected structure. Results depend on method parameters and reference standards, so reported purity values are meaningful only when the analytical conditions are stated. Consistency between laboratories requires comparable protocols and well-characterized reference materials.
Peptides such as ipamorelin are subject to chemical and physical degradation. Hydrolysis of peptide bonds, oxidation of susceptible residues, and aggregation are common pathways that reduce purity over time. The rate of these processes depends on temperature, moisture, pH, and the number of freeze-thaw cycles a sample undergoes. Because the compound is typically handled as a lyophilized powder, controlling moisture during storage is a central concern. Degradation products can be detected with separation techniques that resolve the parent peptide from related impurities.
=== Cot–Cz === Frank Albert Cotton (1930–2007), American chemist known for research on transition metals and as coauthor of Advanced Inorganic Chemistry, 2000 Wolf Prize in Chemistry Charles Coulson (1910–1974), British theoretical chemist, pioneer of the application of quantum theory to problems of molecular structure Archibald Scott Couper (1831–1892), British chemist who developed the concept of tetravalent carbon atoms linking together to form large molecules James Crafts (1839–1917), American chemist, developer of Friedel–Crafts reaction for alkylation and acylation Donald J. Cram (1919–2001), American chemist, winner of the 1987 Nobel Prize in Chemistry for development of molecules with structure-specific interactions of high selectivity William Crookes (1832–1919), British chemist who discovered thallium, and was a pioneer of vacuum tubes Alexander Crum Brown (1838–1922), Scottish organic chemist who developed the concept of tetravalent carbon atoms linking together to form large molecules Paul J.
Most of the remaining nonvisceral fat is found just below the skin in a region called the hypodermis. This subcutaneous fat is not related to many of the classic obesity-related pathologies, such as heart disease, cancer, and stroke, and some evidence even suggests it might be protective. The typically female (or gynecoid) pattern of body fat distribution around the hips, thighs, and buttocks is subcutaneous fat, and therefore poses less of a health risk compared to visceral fat. Like all other fat organs, subcutaneous fat is an active part of the endocrine system, secreting the hormones leptin and resistin. The relationship between the subcutaneous adipose layer and total body fat in a person is often modelled by using regression equations. The most popular of these equations was formed by Durnin and Wormersley, who rigorously tested many types of skinfold, and, as a result, created two formulae to calculate the body density of both men and women. These equations present an inverse correlation between skinfolds and body density—as the sum of skinfolds increases, the body density decreases. Factors such as sex, age, population size or other variables may make the equations invalid and unusable, and, as of 2012, Durnin and Wormersley's equations remain only estimates of a person's true level of fatness. New formulae are still being created.
The creatine phosphate shuttle is an intracellular energy shuttle which facilitates transport of high energy phosphate from muscle cell mitochondria to myofibrils. This is part of phosphocreatine metabolism. In mitochondria, Adenosine triphosphate (ATP) levels are very high as a result of glycolysis, TCA cycle, oxidative phosphorylation processes, whereas creatine phosphate levels are low. This makes conversion of creatine to phosphocreatine a highly favored reaction. Phosphocreatine is a very-high-energy compound. It then diffuses from mitochondria to myofibrils. In myofibrils, during exercise (contraction) ADP levels are very high, which favors resynthesis of ATP. Thus, phosphocreatine breaks down to creatine, giving its inorganic phosphate for ATP formation. This is done by the enzyme creatine phosphokinase which transduces energy from the transport molecule of phosphocreatine to the useful molecule for contraction demands, ATP, an action performed by ATPase in the myofibril. The resulting creatine product acts as a signal molecule indicating myofibril contraction and diffuses in the opposite direction of phosphocreatine, back towards the mitochondrial intermembrane space where it can be rephosphorylated by creatine phosphokinase. At the onset of exercise phosphocreatine is broken down to provide ATP for muscle contraction. ATP hydrolysis results in products of ADP and inorganic phosphate. The inorganic phosphate will be transported into the mitochondrial matrix, while the free creatine passes through the outer membrane where it will be resynthesized into PCr.
Pudzianowski is liberal with his diet and is often seen eating chocolate, ice cream or burgers. On one of the World Strongman events shown on TV, and an interview for MTV, when asked about his diet he said: "I eat everything. I do not follow any particular diet. I eat anything I want, anytime I want".
== External links == Safer Nanomaterials and Nanomanufacturing Initiative Archived 2014-08-12 at the Wayback Machine Clean Tech Law & Business Project on Emerging Nanotechnologies Nanotechnology Lab Archived 2019-12-06 at the Wayback Machine National Nanotechnology Initiative The Berkeley Nanosciences and Nanoengineering Institute Nanotechnology: Green Manufacturing Nanotechnology Now "Can nanotechnology be green?" Folia Water – The Safe Water Book, containing 26 nanosilver-impregnated filter papers for water purification.
Sources: en.wikipedia.org
== External links == hepcidin at the U.S. National Library of Medicine Medical Subject Headings (MeSH) Intrinsic LifeSciences - Hepcidin Research Facility, The BioIron Company Hepcidinanalysis.com - Service for Hepcidin measurements: Scientific Research, Patients and Clinical Trials Protein Data Bank Page PDBe-KB provides an overview of all the structure information available in the PDB for Human Hepcidin
Robin Begley of the American Hospital Association said the case was likely to have a "chilling effect on the culture of safety in health care." The American Nurses Association, the American Association of Critical-Care Nurses, and the National Medical Association all expressed concern that Vaught's prosecution set a "dangerous precedent." The American Nurses Association stated:
=== Ba'athist rule (1963–2024) === Following the 1963 coup, the People's Assembly largely served as a rubber stamp for the ruling Ba'athists. Only parties affiliated with the National Progressive Front could participate in elections. The 2012 elections, held on 7 May, resulted in a new parliament that, for the first time in four decades, was nominally based on a multi-party system. The opposition was represented by the Popular Front for Change and Liberation, which won six seats. It later boycotted the 2016 elections as the government had not upheld its pledges to seek constitutional amendments and pursue political negotiations. In 2016, Hadiya Khalaf Abbas, whom had represented Deir ez-Zor since 2003, became the first woman elected to be the Speaker, whilst in 2017, Hammouda Sabbagh became the first Syriac Orthodox Christian to have held the post.
=== Endogenous sources === ROS are produced during the processes of respiration and photosynthesis in organelles such as mitochondria, peroxisomes and chloroplasts. During the respiration process the mitochondria convert energy for the cell into a usable form, adenosine triphosphate (ATP). The process of ATP production in the mitochondria, called oxidative phosphorylation, involves the transport of protons (hydrogen ions) across the inner mitochondrial membrane by means of the electron transport chain. In the electron transport chain, electrons are passed through a series of proteins via oxidation-reduction reactions, with each acceptor protein along the chain having a greater reduction potential than the previous. The last destination for an electron along this chain is an oxygen molecule. In normal conditions, the oxygen is reduced to produce water; however, in about 0.1–2% of electrons passing through the chain (this number derives from studies in isolated mitochondria, though the exact rate in live organisms is yet to be fully agreed upon), oxygen is instead prematurely and incompletely reduced to give the superoxide radical (•O−2), most well documented for Complex I and Complex III. Another source of ROS production in animal cells is the electron transfer reactions catalyzed by the mitochondrial P450 systems in steroidogenic tissues. These P450 systems are dependent on the transfer of electrons from NADPH to P450. During this process, some electrons "leak" and react with O2 producing superoxide.
Sources: en.wikipedia.org
In 1996, it became a contract research organization (CRO) for the biopharmaceutical sector and entered into collaboration with SmithKline Beecham biologicals (Rixensart, Belgium) for the production of recombinant proteins for phase I, II and III clinical trials. In addition to its pharmaceutical manufacturing activities, Eurogentec became a service company for the biotechnical research industry and university laboratories. In 1999, Eurogentec acquired Oswel Research Product Ltd. a biotechnology company based in Southampton, Great Britain and specialized in the synthesis of chemically modified and complex oligonucleotides and their analogues (DNA, RNA, PNA). In 2002, Eurogentec acquired Wita Proteomics, a company specialized in proteomics services, based in Berlin (Germany). A few months later, Eurogentec installed its US office in San Diego for the production of oligonucleotides (EGT NA).
=== Phase 2 === 7-Oxoprasterone (7-keto-DHEA; HBL-9001; HL-9001; At-Ease) – undefined mechanism of action (immunomodulator) [4] [5] Amdiglurax (ALTO-100; NSI-189) – unknown mechanism of action (hippocampal neurogenesis stimulant and indirect brain-derived neurotrophic factor (BDNF) modulator) [6] [7] BI-1358894 – transient receptor potential cation channel TRPC4 and TRPC5 inhibitor [8] Cannabidiol (A-1002-N5S; CBD; Nantheia™) – cannabinoid, various actions [9] CORT-108297 (ADS-108297) – glucocorticoid receptor antagonist [10] Dronabinol (BX-1) – cannabinoid CB1 and CB2 receptor agonist [11] Iloperidone (Fanapt; Fanaptum; Fiapta; HP-873; ILO-522; VYV-683; Zomaril) – atypical antipsychotic (non-selective monoamine receptor modulator) [12] Ketamine intranasal (Ereska; PMI-100; PMI-150; SLS-002; TUR-002) – NMDA receptor antagonist and dissociative hallucinogen [13] Lithium cocrystal (AL-001; LiProSal; lithium salicylate/L-proline cocrystal) – undefined mechanism of action and mood stabilizer (improved formulation of lithium) [14] Methylone (MDMC; TSND-201) – serotonin–norepinephrine–dopamine releasing agent and entactogen Midomafetamine/citalopram (MDMA/citalopram) – serotonin–norepinephrine–dopamine releasing agent, weak serotonin 5-HT2 receptor agonist, and entactogen followed by a selective serotonin reuptake inhibitor Psilocybin (COMP-360; COMP360) – non-selective serotonin receptor agonist, serotonin 5-HT2A receptor agonist, and psychedelic hallucinogen [15] Psilocybin (MYCO-001, MYCO-003) – non-selective serotonin receptor agonist, serotonin 5-HT2A receptor agonist, and psychedelic hallucinogen [16] Soclenicant (BNC-210; IW-2143) – α7-nicotinic acetylcholine receptor antagonist [17] SRX-246 (API-246) – vasopressin V1A receptor antagonist [18] Xenon (NBTX-001) – NMDA receptor antagonist [19]
== History == In the early 2000s, researchers began exploring the use of PSMA as a target for imaging and therapy. The first PSMA-targeted radiotracer was developed using a different radioactive element, technetium-99m. This radiotracer, called 99mTc-MIP-1404, showed promise in preclinical studies but did not perform well in clinical trials. In 2011, researchers started investigating the use of gallium-68, a different radioactive element, as a more suitable alternative for PSMA-targeted radiotracers. In 2013, the first Ga-PSMA radiotracer was developed by researchers at DKFZ in Germany, and it showed promising results in early clinical studies. Since then, Ga-PSMA has been extensively studied in clinical trials, and it has been found to be a highly effective imaging agent for detecting prostate cancer lesions. It is now widely used in clinical practice, particularly for patients with recurrent prostate cancer and those with high-risk disease. Initially gallium (68Ga) chloride solution injections used for radiolabelling, in 2019 European Pharmacopoeia mentions gallium (68Ga) DOTATOC injection for radiolabelling and PET imaging. Ga 68 PSMA-11 was co-developed by researchers at University of California, Los Angeles and University of California, San Francisco, who conducted a phase III clinical trial. In December 2020, the drug was first approved by the US Food and Drug Administration (FDA) for PET imaging.
Sources: en.wikipedia.org
Both molecules activate the same receptor, GHSR-1a, but they share little sequence identity. Ghrelin is a 28-amino-acid hormone carrying a distinctive acyl modification, whereas ipamorelin is a short synthetic peptide. The shared target explains overlapping endocrine effects, while the different structures account for differences in metabolic stability and receptor selectivity.
Early animal and human studies reported growth hormone release at levels that produced small changes in cortisol, prolactin and adrenocorticotropic hormone. That contrast with older secretagogues gave rise to the selectivity label. The observation is consistent across several reports but rests on a limited number of small studies.
Plasma peptidases cleave the molecule into smaller fragments, and reported half-lives in human studies are on the order of a couple of hours. The identity and activity of individual breakdown products have not been fully mapped. Questions about tissue-level clearance remain open.
It is a synthetic pentapeptide in the growth hormone secretagogue family. The chain contains five residues, two of which are non-natural amino acids.